(Click image to play video)
Avicanna Inc. (TSX: AVCN, OTCQX: AVCNF, Forum) is a diversified and vertically integrated Canadian biopharmaceutical Company that is focused on the research, development, and commercialization of plant-derived cannabinoid-based products for the global consumer, medical, and pharmaceutical market segments.
AVCN’s research is mainly conducted at its R&D headquarters in Toronto’s Johnson & Johnson Innovation Centre in collaboration with leading Canadian academic and medical institutions.
Its product lines include: the derma cosmetic Pura H&W offering, as well as its RHO Phyto medical cannabis line, which is available across Canada in partnership with Medical Cannabis by Shoppers, a subsidiary of
Shoppers Drug Mart.
The company manages its own supply chain from cultivation and extraction through its two majority-owned subsidiaries -
Sativa Nativa SAS and
Santa Marta Golden Hemp SAS in Santa Marta, Colombia. Avicanna cultivates, processes, and commercializes a range of cannabis and hemp cultivars dominant in CBD, CBG, THC, and other cannabinoids for use as active pharmaceutical ingredients.
In this video, Avicanna’s Chief Executive Officer Aras Azadian offers a corporate update for shareholders, dicing into his company’s recent efforts to develop, manufacture, and commercialize plant-derived cannabinoid-based products for its pharmaceutical pipeline.
For more information, please visit
www.avicanna.com.
FULL DISCLOSURE: Avicanna Inc. is a client of Stockhouse Publishing.